BioInformant

Your Global Leader in Stem Cell Market Research

Home » Interviews

BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.

Basilard Biotech to Transform the Engineering of Cell-based Therapies Using Their Novel Nanomechanical Gene Delivery Technology

By

Basilard Biotech LogoBasilard Biotech is a Southern-California-based company poised to lead a revolution in the engineering of cell based therapies in Cell and Gene Therapy (CGT). In 2019, the company launched a disruptive gene delivery technology platform called SoloPore™. This novel approach to nanomechanical gene delivery has the potential to disrupt the current limitations of current viral and non-viral gene delivery—a breakthrough that could facilitate better scalability and more  cost-effective production of cell and gene therapies.

In this interview with Brynley Lee, CEO of Basilard, we learn about the formation of Basilard Biotech, explore the company’s novel SoloPore™ technology, dive into the company’s funding strategy, and explore its future goals. Enjoy! [Read more…]

Disrupting the Cell Therapy Market: Nucleus Biologics Brings Transparency, Customization & Control

By

In recent years, the cell culture company Nucleus Biologics has been at the forefront of market disruption. In this interview with David Sheehan (CEO), we explore how the company has been growing its team, expanding its production capabilities, launching new products, and impressively, rolling out the world’s first online portal for instantaneous custom cGMP cell culture media configuration.

The pace never slows when your mission is to enable lifesaving science! [Read more…]

Interview With Kaz Hirao, President & COO at Fujifilm Cellular Dynamics

By

Fujifilm Cellular Dynamics is the largest provider of induced pluripotent stem cell (“iPSC” or “iPS cell”) products worldwide. In addition to being a global leader for life science products, CDI divided into two business units (Life Science and Therapeutics), positioning it to further invest in the development of iPSC-derived cell therapeutics.

The company also opened a $21M cGMP production facility to support its internal cell therapeutics pipeline, as well as serve as a CDMO for iPS cell products.

[Read more…]

How NanoCellect is Revolutionizing Cell Analysis and Sorting for Stem Cells
(and Other Fragile Samples)

By

NanocellectNanoCellect® is a biotechnology company that facilitates breakthrough biomedical discoveries through cutting-edge cell analysis and sorting technology. Delivering sterile, portable, intuitive solutions for sorting fragile samples (such as stem cells), NanoCellect is pushing the status quo of flow cytometry to empower biomedical scientists with higher viability cells, minimal risk of sample-to-sample contamination, and efficient workflows. [Read more…]

Dr. Robert Hariri on Cell Therapeutics, Combination Therapies, and COVID-19

By

With greater than 30 million cases and 946,000 deaths reported from COVID-19 worldwide, the novel Coronavirus represents one of the largest pandemics in modern history. Thankfully, it also represents the largest cooperative effort in human history.

Globally, scientists are exploring every potential weapon to suppress the threat, including vaccines, repurposed drugs, combination therapies, and as we explore here, cellular therapies with promising cell types such as natural killer (NK) cells and mesenchymal stem cells (MSCs).

In this interview with Dr. Robert Hariri, CEO of Celularity, Inc., we discuss the company’s cell therapeutics pipeline against COVID-19. Enjoy! [Read more…]

BioInformant's World-Class Clients